Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ABL DiagnosticsXPAR:ABLD -6.98%50 3-Year EBITDA Growth Rate is 16.30% as of Dec. 2025, which is 109% above its 10-year median of 7.80. GuruFocus rates XPAR:ABLD with a GF Score™ of 50/100 and a GF Value™ of €8.41 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 525 Healthcare Providers & Services companies, ABL Diagnostics ranks better than 60.38% on this metric.
During the past 12 months, ABL Diagnostics's average EBITDA Per Share Growth Rate was 200.00% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 16.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of ABL Diagnostics was 49.60% per year. The lowest was -44.20% per year. And the median was 7.80% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
ABL Diagnostics 3-Year EBITDA Growth Rate Related Terms
XPAR:ABLD vs VEEV, BTSG, TEM: 3-Year EBITDA Growth Rate Comparison
For the Health Information Services subindustry, ABL Diagnostics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ABL Diagnostics 3-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, ABL Diagnostics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where ABL Diagnostics's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 16.30% mean?
ABL Diagnostics (XPAR:ABLD) has a 3-Year EBITDA Growth Rate of 16.30% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for ABL Diagnostics and its competitors. This is 109% above median its historical median of 7.80. According to the industry distribution chart, ABL Diagnostics ranks #208 out of 525 companies in the Healthcare Providers & Services industry, placing it in the top 39.6%.
Is ABL Diagnostics' 3-Year EBITDA Growth Rate too high?
ABL Diagnostics' current 3-Year EBITDA Growth Rate of 16.30% is 109% above median its 10-year median of 7.80. The Healthcare Providers & Services industry median 3-Year EBITDA Growth Rate is 9.90. ABL Diagnostics' value of 16.30% is 64.6% above this industry median. Based on the distribution chart, ABL Diagnostics ranks #208 out of 525 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, ABL Diagnostics has a GF Score™ of 50/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ABL Diagnostics' 3-Year EBITDA Growth Rate compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, ABL Diagnostics ranks #208 out of 525 companies for 3-Year EBITDA Growth Rate. This puts ABL Diagnostics in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 9.90. ABL Diagnostics' value of 16.30% is 64.6% above this benchmark. While the company's 10-year median is 7.80 vs. the industry median of 9.90, ABL Diagnostics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EBITDA Growth Rate among Healthcare Providers & Services companies is 9.90, based on 525 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ABL Diagnostics's current 3-Year EBITDA Growth Rate of 16.30% is 64.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for ABL Diagnostics and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EBITDA Growth Rate is 9.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ABL Diagnostics's current 3-Year EBITDA Growth Rate is 16.30%, which is 109% above median its own 10-year median of 7.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ABL Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, ABL Diagnostics (XPAR:ABLD) is currently considered Significantly Undervalued. The stock's GF Value™ is €8.41, compared to a current price of €2.40 — trading 71.5% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 16.30%, which is 109% above median its 10-year median of 7.80 and 64.6% above the Healthcare Providers & Services industry median of 9.90. ABL Diagnostics' overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For ABL Diagnostics (XPAR:ABLD), the current 3-Year EBITDA Growth Rate is 16.30% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ABL Diagnostics (XPAR:ABLD) Overvalued in 2026?
Based on GuruFocus' analysis, ABL Diagnostics stock appears to be undervalued.
The current stock price of €2.40 is trading 71.5% below its estimated GF Value™ of €8.41.
GuruFocus considers ABL Diagnostics to be Significantly Undervalued.
Key valuation signals for XPAR:ABLD:
3-Year EBITDA Growth Rate: 16.30% (109% above median its 10-year median of 7.80)
GF Value™: €8.41 vs. price of €2.40 (71.5% below fair value)
Industry Position: 64.6% above the Healthcare Providers & Services median (#208 of 525)
No single metric tells the full story. See the XPAR:ABLD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ABL Diagnostics is a diagnostic and medical software company. The group has focused on the development of software for collecting and processing medical databases, measuring the quality of care, diagnosing infectious diseases by genotyping, and providing decision support for doctors and nurses, virology and microbiology laboratories, and researchers dealing with patients suffering from chronic and complex diseases. It also develops, manufactures, and markets kits for clinical specimen collection.
50GF Score
Get the complete analysis for XPAR:ABLD
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:ABLD has been successfully added to your 
